Next Article in Journal
Surface Modification of 3D Printed PLA Objects by Fused Deposition Modeling: A Review
Previous Article in Journal
Adsorption of Uranium (VI) from Aqueous Solutions by Amino-functionalized Clay Minerals
Previous Article in Special Issue
Production of a Biosurfactant by Cunninghamella echinulata Using Renewable Substrates and Its Applications in Enhanced Oil Spill Recovery
Open AccessArticle

Release of Pharmaceutical Peptides in an Aggregated State: Using Fibrillar Polymorphism to Modulate Release Levels

1
Interdisciplinary Nanoscience Centre (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 14, DK-8000 Aarhus C, Denmark
2
Department of Pharmaceutical Development, Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup, Denmark
3
Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, DK-8000 Aarhus C, Denmark
*
Authors to whom correspondence should be addressed.
Colloids Interfaces 2019, 3(1), 42; https://doi.org/10.3390/colloids3010042
Received: 8 October 2018 / Revised: 15 March 2019 / Accepted: 15 March 2019 / Published: 26 March 2019
(This article belongs to the Special Issue Biosurfactants: Trends and Applications)
Traditional approaches to achieve sustained delivery of pharmaceutical peptides traditionally use co-excipients (e.g., microspheres and hydrogels). Here, we investigate the release of an amyloidogenic glucagon analogue (3474) from an aggregated state and the influence of surfactants on this process. The formulation of peptide 3474 in dodecyl maltoside (DDM), rhamnolipid (RL), and sophorolipid (SL) led to faster fibrillation. When the aggregates were subjected to multiple cycles of release by repeated resuspension in fresh buffer, the kinetics of the release of soluble peptide 3474 from different surfactant aggregates all followed a simple exponential decay fit, with half-lives of 5–18 min and relatively constant levels of release in each cycle. However, different amounts of peptide are released from different aggregates, ranging from 0.015 mg/mL (3475-buffer) up to 0.03 mg/mL (3474-DDM), with 3474-buffer and 3474-RL in between. In addition to higher release levels, 3474-DDM aggregates showed a different amyloid FTIR structure, compared to 3474-RL and 3474-SL aggregates and a faster rate of degradation by proteinase K. This demonstrates that the stability of organized peptide aggregates can be modulated to achieve differences in release of soluble peptides, thus coupling aggregate polymorphism to differential release profiles. We achieved aggregate polymorphism by the addition of different surfactants, but polymorphism may also be reached through other approaches, including different excipients as well as changes in pH and salinity, providing a versatile handle to control release profiles. View Full-Text
Keywords: drug release; surfactant; amyloid aggregation; solubility; polymorphism drug release; surfactant; amyloid aggregation; solubility; polymorphism
Show Figures

Figure 1

MDPI and ACS Style

Madsen, J.K.; Christiansen, G.; Giehm, L.; Otzen, D.E. Release of Pharmaceutical Peptides in an Aggregated State: Using Fibrillar Polymorphism to Modulate Release Levels. Colloids Interfaces 2019, 3, 42.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop